John M. Streicher, Ph.D

 Assistant Professor, Pharmacology

University of Arizona College of Medicine
Department of Pharmacology
LSN563 – PO Box 245050, 1501 N. Campbell Ave.
Tucson, AZ 85724-5050
 

Phone: 
520-626-7495
Email Address: 
jstreicher@email.arizona.edu
Education: 
  • Doctor of Philosophy; Molecular, Cellular and Integrative Physiology; University of California – Los Angeles (UCLA); Los Angeles, CA, 2009.
  • Master of Science; Physiology and Pharmacology; Oregon Health and Science University (OHSU); Portland, OR, 2002.
  • Bachelor of Science; Biology; George Fox University; Newberg, OR, 1999
Honors & Awards: 
  • Travel Award, International Narcotics Research Conference (INRC), July 2016.
  • Travel Award, International Narcotics Research Conference (INRC), June 2015.
  • Travel Award, International Narcotics Research Conference (INRC), July 2014.
  • Abstract (Moses-Fynn et al. 2014) selected for special publicity at the 30th Annual Meeting of the American Academy of Pain Medicine (http://www.newswise.com/articles/chronic-pain-researchers-first-to-link-regulatory-protein-to-mu-opioid-receptor-signaling)
  • ASPET Young Scientist Travel Award, Experimental Biology Conference, April 2011.
  • Streicher et al. (2010) (Circulation Research) featured on MDLinx.com, a research indexing site for physicians.  http://www.mdlinx.com/heartlinx/news-article.cfm/3096007
  • Department of Molecular Medicine (DMM) Excellence in Science Award for Best Poster Presentation, DMM Annual Retreat, March 2009.
  • Best Poster Presentation Award, 4th Annual Molecular, Cellular and Integrative Physiology Retreat, March 2008.
  • Graduate With Science Honors, magna cum laude, George Fox University, 1999.
Major Areas of Research Interest: 

I have a strong interest in how signal transduction cascades downstream of the opioid receptors work. Using a variety of cell biology, molecular biology, and animal techniques, I find new signaling regulators of the opioid receptors, and determine how they work in living animals. I then use this knowledge to design novel strategies for drug discovery to create new analgesic drugs without the side effects and drawbacks of current opioid drugs like morphine.

 

Selected Publications: 
  • Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE. 2016. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) modulating the mu opioid receptor in a biased fashion. ACS Chemical Neuroscience. 7(3):297-304.
  • Stevenson GW, Luginbuhl A, Dunbar C, LaVigne J, Dutra J, Atherton P, Bell B, Cone K, Giuvelis D, Polt R, Streicher JM, Bilsky EJ. 2015. The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference, but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence. Pharmacology, Biochemistry and Behavior. 132:49-55.
  • Frankowski KJ, Slauson SR, Lovell KM, Phillips AM, Streicher JM, Zhou L, Whipple D, Schoenen FJ, Prisinzano TE, Bohn LM, Aube J. 2015. Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif. Bioorganic and Medicinal Chemistry. 23(14):3948-56.
  • Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ. 2014. Behavioral and Cellular Pharmacology Characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan (NAQ) as a Mu Opioid Receptor Selective Ligand. European Journal of Pharmacology. 736:124-30.
  • Schmid CL, Streicher JM, Meltzer HY, Bohn LM. 2014. Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt. Neuropsychopharmacology. 39(8):1902-13..
  • Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, Madoux F, Cameron MD, Prisinzano TE, Aube J, Bohn LM. 2013. Development of functionally selective, small molecule agonists at kappa opioid receptors. Journal of Biological Chemistry. 288(51):36703-16.
  • Schmid CL, Streicher JM (Co-First Author), Groer CE, Munro TA, Zhou L and Bohn LM. 2013. Functional Selectivity of 6’-guanidinonaltrindole (6’-GNTI) at Kappa Opioid Receptors in Striatal Neurons. Journal of Biological Chemistry. 288(31):22387-98.
  • Frankowski KJ, Hedrick MP, Gosalia P, Li K, Shi S, Whipple D, Ghosh P, Prisinzano TE, Schoenen F, Su Y, Vasile S, Sergienko E, Gray W, Hariharan S, Milan L, Heynen-Genel S, Mangravita-Novoc A, Vicchiarelli M, Smith L, Streicher JM, Caron MG, Barak LS, Bohn LM, Chung T, Aube J.  2012.  Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.  ACS Chemical Neuroscience.  3(3):221-236.
  • Beguin C, Potuzak J, Xu W, Liu-Chen L, Streicher JM, Groer CE, Bohn LM, Carlezon WA, Cohen BM.  2012.  Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.  Bioorganic & Medicinal Chemistry Letters.  22(2):1023-6.
  • Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Bohn LM and Micalizio GC. 2011.  Synthesis of conolidine and discovery of a potent non-opioid analgesic for tonic and persistent pain.  Nature Chemistry3(6):449-53.
  • Drews O, Tsukamoto O, Liem D, Streicher J, Wang Y, Ping P.  2010.  Differential Regulation of Proteasome Function in Isoproterenol-Induced Cardiac Hypertrophy.  Circulation Research.  107(9):1094-1101.
  • Papanicolaou KN, Streicher JM, Ishikawa TO, Herschman H, Wang Y, Walsh K.  2010.  Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.  Journal of Molecular and Cellular Cardiology.  49(2):196-209.
  • Streicher JM, Ren S, Herschman H, Wang Y.  2010.  MAPK-Activated Protein Kinase-2 in Cardiac Hypertrophy and Cyclooxygenase-2 Regulation in Heart.  Circulation Research.  106(8):1434-43.
  • Streicher JM, Kamei K, Ishikawa TO, Herschman H, Wang Y.  2010.  Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice.  Journal of Molecular and Cellular Cardiology.  49(1):88-94.
  • Streicher JM and Wang Y.  2008.  The Role of COX-2 in Heart PathologyCardiovascular and Hematological Agents in Medicinal Chemistry.  6:69-79.
  • Bethea CL, Streicher JM, Mirkes SJ, Sanchez RL, Reddy AP and Cameron JL.  2005.  Serotonin-Related Gene Expression in Female Monkeys with Individual Sensitivity to Stress.  Neuroscience.  132(1):151-66.
  • Huan JY, Streicher JM, Bleyle LA and Koop DR.  2004.  Proteasome-dependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells.  Toxicology and Applied Pharmacology.  199(3):332-43.
  •  Bethea CL, Streicher JM, Coleman K, Pau FK, Moessner R, and Cameron JL.  2003.  Anxious behavior and fenfluramine-induced prolactin secretion in young rhesus macaques with different alleles of the serotonin reuptake transporter polymorphism (5HTTLPR).  Behavior Genetics.  34(3):295-307.
  •  Bethea CL, Lu NZ, Reddy A, Shlaes T, Streicher JM and Whittemore SR.  2003.  Characterization of reproductive steroid receptors and response to estrogen in a rat serotonergic cell line.  Journal of Neuroscience Methods. 127:31-41.
  • Bethea CL, Lu NZ, Gundlah C, Streicher JM.  2002.  Diverse actions of ovarian steroids in the serotonin neural system.  Frontiers in Neuroendocrinology.  23:41-100.
Research Activities: 
  • NIH R43 (SBIR), DA042634, to develop long-acting peripherally-restricted kappa opioid agonists for the treatment of chronic pain. Co-Investigator, Peptide Logic (Pierre Riviere) PI. Project period 8/1/2016 – 1/31/2017.
  • UA Faculty Seed Grant to determine the anti-cancer molecular target of cannabinoid drugs. Principal Investigator. Project period 8/1/2016 – 7/31/2017.
  • UA Arizona Area Health Education Centers (AzAHEC) research grant to determine the molecular mechanism of functionally selective signaling by endomorphin peptides at the mu opioid receptor. Principal Investigator. Project period 2/22/2016 – 8/21/2016.
  • NIH R01, DA038635, to develop novel bifunctional ligands for the treatment of chronic pain. Co-Investigator, Sam Ananthan PI. Project period 8/1/2015 – 6/30/2020.
  • NIH R01, NS091238, to develop novel glycosylated PACAP agonists for the treatment of Parkinson’s disease. Co-PI, Robin Polt PI. Project period 9/30/2015 – 6/30/2020.
NIH High School Student Research Program: 

 Faisa Warsame, Corona del Sol High School, 2016

Last Updated: 
July 28, 2016